bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 2,060 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $100.16, for a total transaction of $206,329.60. Following the transaction, the insider now owns 34,616 shares of the company’s stock, valued at approximately $3,467,138.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Davidson also recently made the following trade(s):
- On Friday, July 5th, David Davidson sold 7,660 shares of bluebird bio stock. The shares were sold at an average price of $129.47, for a total value of $991,740.20.
Shares of BLUE traded down $0.71 on Wednesday, hitting $101.08. The company’s stock had a trading volume of 563,443 shares, compared to its average volume of 544,411. The company has a market capitalization of $5.59 billion, a PE ratio of -9.46 and a beta of 2.28. bluebird bio Inc has a fifty-two week low of $87.49 and a fifty-two week high of $163.43. The company has a 50 day moving average price of $116.88 and a 200 day moving average price of $132.31. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.02 and a quick ratio of 8.02.
Institutional investors have recently bought and sold shares of the business. Trust Co. of Vermont raised its holdings in shares of bluebird bio by 40.6% in the second quarter. Trust Co. of Vermont now owns 253 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 73 shares during the last quarter. LPL Financial LLC lifted its position in bluebird bio by 1.6% during the 2nd quarter. LPL Financial LLC now owns 5,373 shares of the biotechnology company’s stock worth $683,000 after buying an additional 84 shares in the last quarter. Capital Investment Advisory Services LLC lifted its position in bluebird bio by 100.0% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. First Light Asset Management LLC lifted its position in bluebird bio by 0.5% during the 2nd quarter. First Light Asset Management LLC now owns 18,840 shares of the biotechnology company’s stock worth $2,396,000 after buying an additional 103 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in bluebird bio by 18.2% during the 1st quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 129 shares during the last quarter.
Several equities research analysts have recently weighed in on BLUE shares. Gabelli reiterated a “buy” rating on shares of bluebird bio in a research note on Friday, July 19th. BidaskClub downgraded bluebird bio from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 28th. Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a research note on Tuesday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $195.00 price target on shares of bluebird bio in a research note on Thursday, June 13th. Finally, Morgan Stanley lowered their price target on bluebird bio from $143.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $154.13.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Recommended Story: Sell-Side Analysts
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.